Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Investigating brain changes in patients with progressive apraxia of speech

Official title: Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech

Run by Mayo Clinic · NCT01818661 · Data updated 2026-11-12

This study is trying to see how changes in the brain affect speech difficulties over time in people with progressive apraxia of speech.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorMayo Clinic
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Rochester, Minnesota)
StatusRecruiting
StartedJuly 1, 2018
Main results expectedJune 2028
Study endsJune 2028
Registry record updatedNovember 12, 2025
Trial IDNCT01818661 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals diagnosed with neurodegenerative apraxia of speech at the Mayo Clinic.

Probably not a fit

Patients with speech and language deficits due to concurrent illnesses like traumatic brain injury or strokes will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the relationship between structural and functional brain changes observed through imaging techniques and the progression of speech and language difficulties in patients diagnosed with neurodegenerative apraxia of speech (AOS). It focuses on understanding how AOS, often associated with non-fluent aphasia, manifests and evolves over time, potentially leading to cognitive impairments. The study will utilize AV-1451 as an intervention to assess these changes in a longitudinal manner, providing insights into the neurological underpinnings of the disorder.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients suffering from apraxia of speech and related conditions.

How similar studies have gone: While there is ongoing research in related areas, this specific approach focusing on the longitudinal imaging of AOS is relatively novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic

Exclusion Criteria:

* Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded.
* Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan.
* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy).
* Subjects will also be excluded if they do not have an informant, or do not consent to research.

Where it's running

  • Mayo Clinic
    Rochester, Minnesota, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.